Logo image of IOBT

IO BIOTECH INC (IOBT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IOBT - US4497781090 - Common Stock

0.6645 USD
+0.04 (+6.83%)
Last: 12/19/2025, 8:00:02 PM
0.6699 USD
+0.01 (+0.81%)
After Hours: 12/19/2025, 8:00:02 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to IOBT. IOBT was compared to 530 industry peers in the Biotechnology industry. Both the profitability and financial health of IOBT have multiple concerns. IOBT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IOBT has reported negative net income.
In the past year IOBT has reported a negative cash flow from operations.
In the past 5 years IOBT always reported negative net income.
In the past 5 years IOBT always reported negative operating cash flow.
IOBT Yearly Net Income VS EBIT VS OCF VS FCFIOBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -221.12%, IOBT is doing worse than 91.35% of the companies in the same industry.
The Return On Equity of IOBT (-9698.02%) is worse than 83.46% of its industry peers.
Industry RankSector Rank
ROA -221.12%
ROE -9698.02%
ROIC N/A
ROA(3y)-45.97%
ROA(5y)-105.42%
ROE(3y)-50.49%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IOBT Yearly ROA, ROE, ROICIOBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 600 800

1.3 Margins

IOBT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IOBT Yearly Profit, Operating, Gross MarginsIOBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, IOBT has about the same amount of shares outstanding.
The number of shares outstanding for IOBT has been increased compared to 5 years ago.
IOBT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IOBT Yearly Shares OutstandingIOBT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
IOBT Yearly Total Debt VS Total AssetsIOBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

IOBT has an Altman-Z score of -20.90. This is a bad value and indicates that IOBT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of IOBT (-20.90) is worse than 84.40% of its industry peers.
IOBT has a Debt/Equity ratio of 18.29. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 18.29, IOBT is doing worse than 83.27% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 18.29
Debt/FCF N/A
Altman-Z -20.9
ROIC/WACCN/A
WACCN/A
IOBT Yearly LT Debt VS Equity VS FCFIOBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

IOBT has a Current Ratio of 2.01. This indicates that IOBT is financially healthy and has no problem in meeting its short term obligations.
IOBT's Current ratio of 2.01 is on the low side compared to the rest of the industry. IOBT is outperformed by 76.50% of its industry peers.
IOBT has a Quick Ratio of 2.01. This indicates that IOBT is financially healthy and has no problem in meeting its short term obligations.
IOBT has a worse Quick ratio (2.01) than 74.62% of its industry peers.
Industry RankSector Rank
Current Ratio 2.01
Quick Ratio 2.01
IOBT Yearly Current Assets VS Current LiabilitesIOBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.11% over the past year.
EPS 1Y (TTM)5.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, IOBT will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.93% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y35.78%
EPS Next 2Y20.38%
EPS Next 3Y21.45%
EPS Next 5Y13.93%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IOBT Yearly Revenue VS EstimatesIOBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
IOBT Yearly EPS VS EstimatesIOBT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

IOBT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IOBT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IOBT Price Earnings VS Forward Price EarningsIOBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IOBT Per share dataIOBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as IOBT's earnings are expected to grow with 21.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.38%
EPS Next 3Y21.45%

More info and screens

0

5. Dividend

5.1 Amount

IOBT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

IO BIOTECH INC

NASDAQ:IOBT (12/19/2025, 8:00:02 PM)

After market: 0.6699 +0.01 (+0.81%)

0.6645

+0.04 (+6.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)03-16 2026-03-16/amc
Inst Owners48.11%
Inst Owner Change-45.58%
Ins Owners5.14%
Ins Owner Change0%
Market Cap47.81M
Revenue(TTM)N/A
Net Income(TTM)-88.35M
Analysts76.67
Price Target2.51 (277.73%)
Short Float %4.17%
Short Ratio0.92
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.14%
Min EPS beat(2)3.61%
Max EPS beat(2)60.66%
EPS beat(4)3
Avg EPS beat(4)13.97%
Min EPS beat(4)-20.66%
Max EPS beat(4)60.66%
EPS beat(8)5
Avg EPS beat(8)7.94%
EPS beat(12)7
Avg EPS beat(12)5.02%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-69.21%
EPS NQ rev (1m)2.44%
EPS NQ rev (3m)47.02%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 52.48
P/tB 52.48
EV/EBITDA N/A
EPS(TTM)-1.3
EYN/A
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.13
OCFYN/A
SpS0
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -221.12%
ROE -9698.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.97%
ROA(5y)-105.42%
ROE(3y)-50.49%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 18.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.6%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.01
Quick Ratio 2.01
Altman-Z -20.9
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.89%
EPS Next Y35.78%
EPS Next 2Y20.38%
EPS Next 3Y21.45%
EPS Next 5Y13.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.82%
EBIT Next 3Y5.97%
EBIT Next 5Y11.75%
FCF growth 1Y-21.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.91%
OCF growth 3YN/A
OCF growth 5YN/A

IO BIOTECH INC / IOBT FAQ

What is the ChartMill fundamental rating of IO BIOTECH INC (IOBT) stock?

ChartMill assigns a fundamental rating of 1 / 10 to IOBT.


What is the valuation status for IOBT stock?

ChartMill assigns a valuation rating of 1 / 10 to IO BIOTECH INC (IOBT). This can be considered as Overvalued.


What is the profitability of IOBT stock?

IO BIOTECH INC (IOBT) has a profitability rating of 0 / 10.


Can you provide the financial health for IOBT stock?

The financial health rating of IO BIOTECH INC (IOBT) is 3 / 10.